Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders
Get evaluated, discuss your goals, and receive your personalized treatment plan
Clinical studies help clarify the connection: In simple terms: the trigger is the speed of weight loss, not tirzepatide itself
Members access evidence-based protocol guides, detailed dosing information, and a community of experienced researchers who have navigated these exact challenges
Semaglutide is generally considered safe for people with type 2 diabetes or those needing weight loss, but there is no specific research on its safety in people with fibromyalgia
Zhu LQ, Wang SH, Ling ZQ, Wang DL, Wang JZ